TipRanks
Oppenheimer: 2 shares that can climb more than 100%
The markets are taking us all for a roller coaster ride in recent sessions, alternating gains and declines. It’s not exactly what’s coming next, but some of Wall Street’s sharpest thoughts are busy. One of the sharp minds is John Stoltzfus, chief investment strategist and managing director of Oppenheimer. Stoltzfus sees us in the preparatory phases of further market gains, and he goes to great lengths to explain his prospects. While he agrees that we have not yet succeeded in putting the COVID-19 pandemic crisis completely behind us, he points out that the data indicates a resilient economy. Stoltzfus starts with the market for treasury bonds, which he describes as ‘normalization’. Yes, yields have risen over the past few days from historic lows reached late last summer, but the strategist sees it as proof that ‘because the pandemic crisis is likely to bring better times ahead of the US economy’. Stoltzfus continues the recent earnings season. Of the corporate earnings reports, Stoltzfus says: ‘With 97% of the companies in the S&P 500 making a profit, they increased by 5.37% due to a turnover growth of 2.47% – a much stronger result than which expected consensus analysis at the beginning of the year. the season. “But good results are not the only support Stoltzfus offers for his view that better times lie ahead. Stoltzfus points to the rising oil price, noting that its annual rise coincided with the spreading vaccination campaigns and the prospect of economic reopening, and he notes on copper.In his words: “The rise in copper prices serves as a sign that the expectation is that growth in the world will accelerate as the world moves out under the pandemic.” Against this background, one of Stoltzfus’ colleagues at Oppenheimer, the five-star analyst Kevin DeGeeter, followed up on two stocks that he could use as a boon for big gains in a rebound of the market, with 100% or better. led by the TipRanks database to see what other Wall Street analysts have to say about it Evaxion Biotech (EVAX) The first Oppenheimer choice we look at is Evaxion, a biotechnology company that uses proprietary AI immunology platforms to develop new immunotherapies for the treatment of various cancers and infectious diseases.The company currently has two immunotherapy candidates in the clinical trial stage for various cancers, and two other candidates in preclinical research.Evaxion was announced on the NASDAQ in early February and announced the price of the IPO announced on February 4 and closed the offer on February 10. The shares were at $ 10 each, the bottom end of the range, and the company has 3 million shares lies on the market, with a gross return of $ 30 million. The most important point for Evaxion, as far as investors are concerned, is the two candidates in Phase IIa clinical trials. The candidates, EVX-01 and EVX-02, are designed to be patient-specific treatments for non-small cell lung cancer, bladder cancer and various types of melanoma. Results for both candidates’ studies are expected in the first half of 2021. DeGeeter began covering this stock in early March, basing its optimism on ‘1) Artificial intelligence-driven immunology platform generating a broad portfolio; 2) personalized cancer vaccines, EVX-01 and EVX-02, with two major Phase I / IIa updates in 2Q21; 3) capital-efficient business mode … ”DeGeeter writes in conclusion:“ We consider EVAX to be an AI platform story with multiple differentiated programs in early-stage human studies or in clinical development. Our short-term focus is on the oncology platform … ”In line with its optimistic outlook, DeGeeter rates EVAX as a better performer (ie buy), and its $ 18 price target implies a solid upward rise of 157% for the coming year. (To see DeGeeter’s record, click here. DeGeeter’s review is one of two published on EVAX, but both are Buys, which makes the consensus a moderate buy here. The stock sells for $ 7 and the average price target is $ 18, same as DeGeeter. (See EVAX stock analysis on TipRanks) Sensei Biotherapeutics (SNSE) We remain in the biotechnology industry for the second share on our Oppenheimer shortlist. Like Evaxion above, Sensei Biotherapeutics is an immunotherapy research company with the focus on cancer treatments; what makes Sensei different is its platform by using a bacteriophage to deliver the therapeutic agent and elicit an immune response in the patient.In another agreement with Evaxion, Sensei released its IPO in February The company put 7 million common stock on the market at a price of $ 19 per share and closed the first day trading at $ 18.90, earning a total of $ 152.6 million. en di The company now boasts a market capitalization of $ 418 million. The company’s leading candidate, SNS-301, is an experimental cancer vaccine targeting the overexpression of aspartyl beta hydroxylase (ASPH) in head and neck squamous cell carcinoma. The product is in Phase I / II development, and preliminary data have shown a long reaction time, including stability of more than 30 weeks in 2 patients. Further data are expected in the second half of this year. In his note starting coverage on Sensei Biotherapeutics, DeGeeter takes an optimistic view. “We view SNSE’s ImmunoPhage Immuno-Oncology Platform as an important differentiation based on 1) potential to easily combine cheap off-the-shelf and personalized neopitopes in one product, 2) self-adjuvant profile of ImmunoPhage, and 3) rapid reversal of ~ four weeks for personalized neopitope production. Our positive outlook is based on the potential for Phase I / II study of SNS-301 ASPH ImmunoPhage to demonstrate clinically significant benefit in first-class treatment and neoadjuvant head and neck cancer settings based on improved response durability, ”said DeGeeter. To this end, DeGeeter proposes an outperform (ie buy) rating on SNSE shares, coupled with a $ 36 price target indicating the potential for ~ 141% upside over the next 12 months. (To see DeGeeter’s record, click here.) Sensei has only been a public company for a few weeks, but in that time he has drawn 4 analyst ratings – all of them are Buys, who buy the analyst’s consensus a unanimous strong make. Shares cost $ 14.95 and have an average price target of $ 29.50, implying an upward one-year high of ~ 97%. (See SNSE stock analysis on TipRanks.) To find great ideas for stocks trading at attractive valuations, visit TipRanks ‘best-selling stocks, a newly launched tool that combines all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the proposed analysts. The content is for informational purposes only. It is very important to do your own analysis before investing.